MANNKIND CORP — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
MannKind achieved three major catalysts in Q2 2026: FDA approval of Afrezza pediatric indication (May 29), FDA approval of Furoscix ReadyFlow autoinjector (July 23), and positive Phase 1b data for nintedanib DPI (MNKD-201) in IPF patients. Total revenues grew 43% to $109.4M in Q2 2026 vs. $76.5M in Q2 2025, driven by Furoscix acquisition contribution ($22.2M sales) and collaboration revenue increases, though Afrezza sales declined 7% YoY to $17.0M. Operating loss was $350K in Q2 2026 vs. $5.3M income in Q2 2025, and net loss was $19.0M vs. $668K net income, reflecting 84% increase in SG&A expenses to $58.3M for commercial launches.
Why this rating
Three FDA approvals and strong 43% revenue growth are material positive catalysts for a $1.1B company. However, net operating losses despite revenue growth, high debt burden ($319M term loan), and stockholders' deficit of $67.2M offset optimism. Event is significant but tempered by execution risks and cash burn trajectory.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.